FIELD: pharmaceuticals.
SUBSTANCE: invention relates to a novel compound of formula 1, or a pharmaceutically acceptable salt thereof, which may find use in the prevention or treatment of resistant cancer. In the said formula, R1 is hydrogen, linear or branched C1~C6alkyl, C6~C12aryl or C1~C6alkyl C6~C12aryl, each of which may be independently substituted with at least one substituent selected from halo, C1~C6alkyl, C3~C6cycloalkyl and C6~C12aryl; R3 is hydrogen, C1~C6alkoxy, halogen, where C1~C6alkoxy can be substituted with C1~C6alkyl C6~C12aryl; L1 is C1~C10alkylene, where alkylene may be substituted by oxo; Q is S, NR where R is hydrogen, linear or branched C1~C6alkyl, C6~C12aryl or C1~C6alkyl C6~C12aryl, each of which may be independently substituted with at least one substituent selected from C3~C7cycloalkyl and C6~C12aryl; R2 is hydrogen, linear C1~C6alkyl, C3~C7cycloalkyl, C6~C12aryl, 3–12 membered heteroaryl containing a ring heteroatom selected from N, C1~C6alkyl C6~C12aryl, each of which may be independently substituted with at least one substituent selected from halo, C1~C6alkyl, C1~C6alkoxy, C6~C12aryl, nitro, cyano or trifluoromethyl; or R2 is 
; R4 is hydrogen, linear or branched C1~C6alkyl, C3~C7cycloalkyl, C2~C6alkynyl, C1~C6alkylthio, C6~C12aryl, C1~C6alkyl-C6~C12aryl, each of which may be independently substituted with at least one substituent selected from halo, C6~C12aryl, C6~C12aryloxy, nitro, cyano or trifluoromethyl; R2 and R4 can be combined to form a 5–10 membered monocyclic or bicyclic ring, R4' is hydrogen; m is an integer 1 and n is an integer with a value from 1 to 4; and X, Y and Z are each hydrogen, R1 and R2 are not simultaneously hydrogen or simultaneously linear alkyl. The invention also relates to a pharmaceutical composition containing a compound of formula 1 for the prevention or treatment of cancer or a resistant form of cancer, a method of treating cancer that is resistant to oncological therapies, the use of a compound of formula 1 for the production of a medicinal product for the treatment of cancer or a resistant form of cancer and cancer stem cells.
[Formula 1]
EFFECT: obtaining a new compound and a pharmaceutical composition containing the compound for the prevention or treatment of cancer.
11 cl, 37 dwg, 1 tbl, 92 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NEW COMPOUND AND PHARMACEUTICAL COMPOSITION FOR INCREASING ANTICANCER ACTIVITY, CONTAINING SAID COMPOUND | 2019 |
|
RU2781282C1 |
| BICYCLIC COMPOUND AND USE THEREOF FOR SUV39H2 INHIBITION | 2016 |
|
RU2729187C1 |
| THERAPEUTIC AGENTS AIMED AT SHORTENED PROTEINS OF ADENOMATOUS POLYPOSIS COLI (APC) | 2014 |
|
RU2727516C2 |
| COMPOUNDS USEFUL AS PESTICIDES, AND INTERMEDIATE COMPOUNDS, COMPOSITIONS AND METHODS RELATED THERETO | 2016 |
|
RU2821715C2 |
| AZALACTAM COMPOUNDS AS HPK1 INHIBITORS | 2019 |
|
RU2801140C2 |
| ENZYME-ACTIVATING COMPOUNDS AND COMPOSITIONS | 2013 |
|
RU2652989C2 |
| COMPOUNDS AND METHODS FOR ENHANCED DEGRADATION OF TARGET PROTEINS AND OTHER POLYPEPTIDES BY AN E3 UBIQUITIN LIGASE | 2013 |
|
RU2666530C2 |
| QUINOLINIL-CONTAINING COMPOUND, ITS PHARMACEUTICAL COMPOSITION AND USE | 2020 |
|
RU2803116C2 |
| COMPOUNDS AND METHODS FOR ENHANCING DEGRADATION OF TARGET PROTEINS AND OTHER POLYPEPTIDES, USING E3 UBIQUITIN LIGASE | 2013 |
|
RU2781452C2 |
| INHIBITOR COMPOUNDS | 2013 |
|
RU2673079C2 |
